August 2015- Volume 11, Issue 8

August 2015

In this Issue

Preclinical

Early-stage immunotherapy

Early-stage immunotherapy

Genticel announces proof of concept for HPV therapeutic vaccine

Waste not, want not

Waste not, want not

GBSI survey says U.S. squanders $28 billion annually on flawed preclinical research, stalling discovery of new therapies

Going right to the head

Going right to the head

TNX-201 demonstrates significant analgesic effects in animal models of migraine and chronic pain

Two for the price of one

Two for the price of one

Elsalys Biotech nets rights for anti-CD160 antibody with anti-angiogenic, immunomodulatory effects

Business & Government Policy

Pfizer launches precision medicine center in Chile

Pfizer launches precision medicine center in Chile

Thermo Fisher joining the effort as a corporate sponsor in initial lung cancer project

The M&A roundup

The M&A roundup

Catching up with the latest big news and rumors of mergers and acquisitions

Crowdsourced diligence insights for investors

Crowdsourced diligence insights for investors

First-of-its-kind product from Propel(x) brings democratized approach that is useful for complex deep technology situations

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Kythera going for $2.1 billion

Kythera going for $2.1 billion

Allergan looks to bolster existing facial aesthetics business with acquisition

Discovery

One step at a time against Alzheimer’s

One step at a time against Alzheimer’s

Brain inflammation targeted in first drug discovery project from Dementia Consortium

Ubiquitous ubiquitins?

Ubiquitous ubiquitins?

Almac Discovery and Genentech partner on ubiquitin-related target for potential cancer drugs

‘We are the world’

‘We are the world’

Open Innovation Drug Discovery program expands to bring academia, scientists, researchers, biotechs together across the globe

An initial partnership for Invenra

An initial partnership for Invenra

Biopharmaceutical company strikes mAb deal with Oxford BioTherapeutics

Research & Development

NuGEN sampling effort could accelerate cancer research

NuGEN sampling effort could accelerate cancer research

Scientists at NuGEN Technologies Inc. have simultaneously surveyed the RNA of more than 400 targeted genes in a single assay using next-generation sequencing

Casting off with CD206

Casting off with CD206

BIND and Macrophage to explore possibility of Manocept-linked Accurins to target disease-associated macrophages

From the ground up with uPAR

From the ground up with uPAR

Cancer Research UK invests in startup company’s novel cancer treatment

UK companies pair on libraries targeting the ubiquitin system

UK companies pair on libraries targeting the ubiquitin system

Agreement combines Ubiquigent biology expertise with Cyclofluidic chemistry platform to identify small-molecule libraries

Predicting survival

Predicting survival

UCSD researchers use biomarkers to gauge response to chemotherapy

Clinical Trials

Three years and a trio of targets

Three years and a trio of targets

Epizyme, Celgene extend joint agreement on epigenetic therapies for cancer worth up to $610 million

A taste of one’s own medicine

A taste of one’s own medicine

Clinical data shows promise of durable results with CAR T cell therapy

CSL Behring advances therapeutics for hemophilia

CSL Behring advances therapeutics for hemophilia

Novel recombinant factor VIII single chain aimed at adolescents and adults

Guselkumab demonstrates efficacy in plaque psoriasis

Guselkumab demonstrates efficacy in plaque psoriasis

Phase 2b results show that blockade of IL-23 resulted in significant skin clearance, with improvements through week 40

Diagnostics

Onward and upward for OPKO

Onward and upward for OPKO

Company clears first hurdle in its acquisition of Bio-Reference Laboratories

Diagnosing cancer with bacteria

Diagnosing cancer with bacteria

Engineered probiotics can reportedly detect tumors in the liver

A gut feeling about biotherapy

A gut feeling about biotherapy

Study shows predictive role of biotherapy monitoring in inflammatory bowel disease

Dialing up diagnostic efforts

Dialing up diagnostic efforts

QIAGEN kicks off a trio of diagnostic-focused partnerships in June and July

Q&A

Q&A: Mush, you huskies!

Q&A: Mush, you huskies!

DDNews talks to Sujay Jadhav of goBalto about the origin and direction of his company

Editor's Focus

Dog days of summer. Dog years of oncology?

Dog days of summer. Dog years of oncology?

According to economists at MIT, companies are underinvesting in long-term research on new cancer-fighting drugs; we should probably be concerned about that

Commentary

Of minimum wage and cancer drugs

Of minimum wage and cancer drugs

They may not seem to be 'two great tastes that go great together' but columnist Peter Kissinger has some lessons and thoughts that arise from considering boosts to minimum wages and the costs of cancer therapeutics

Guest Commentary: An industrywide call for greater antibody information

Guest Commentary: An industrywide call for greater antibody information

Many in recent years have highlighted unreliability and irreproducibility of much science research, adding up to an estimated $28 billion wasted each year in irreproducible preclinical research in the United States alone and, arguably, the greatest need for change lies in the field of commercial antibodies
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2021 Issue Front Cover

Latest Issue  

• Volume 17 • Issue 11 • November 2021

November 2021

November 2021 Issue